The company was founded in 2001 and listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange in 2021; it is an innovation-driven pharmaceutical manufacturer with multiple R&D centers and global innovation resources, covering the traditional Chinese medicine, chemical medicine, and biomacromolecule drug industry chain, based in China and with a global layout. The company is a high-tech enterprise whose main business is R&D, production and sales of chemical preparations, chemical raw materials and traditional Chinese medicine preparations. It already has the production capacity of tablets, capsules, granules, powders, dry suspensions, inhalation solutions, small-volume injections, eye drops, freeze-dried powder injections, etc., as well as chemical raw drug products. The main products are: colloidal bismuth pectin, montmorillonite, pantoprazole sodium, fosfomycin, trometamycin, ferrous succinate, sodium docusate, morpholecyl ester, etc. Corporate honors: 2020 Independent Innovation Award, 2020 Tax Contribution Award, 2020 Intelligent Development Award, 2020 Scale Development Award, etc.
相关临床试验
15
6 进行中
药物批准
91
批准总数
监管机构
1
监管机构数
成立时间
2001
进行中(未招募)
3
20.0%
已完成
5
33.3%
尚未招募
3
20.0%
招募中
2
13.3%
终止
1
6.7%
Unknown
1
6.7%
暂无资讯文章